MetaVia Inc. (MTVA)
Last updated: 2026-10-24 15:04:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
MetaVia Inc. (MTVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.39, with a market capitalization of $9.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $14.85. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$9.16M | |
$1.39 | |
$30.25 | |
$0.97 | |
$1.39 | |
99.27K | |
76.69K | |
-- | |
$14.85 | |
$0.97 | |
-- | |
-- |
MetaVia Inc. (MTVA) Latest Closing Stock Price
MetaVia Inc. (MTVA) last closed at $1.39 as of 2026-10-23 23:31:00, unchanged from the previous close of $1.39.
During the latest regular trading session, MTVA traded between $0.97 and $30.25, with a volume of 99.27K shares. The closing price was near the lower end and near the lower end of its 52-week range.
MetaVia Inc. (MTVA) 7-Day Stock Price Change
Over the past seven days, MetaVia Inc. (MTVA) moved from $1.37 to $1.39, representing a gain of 1.31% ($0.02).
The stock traded between $1.20 and $1.50 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 54.23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
MTVA 52-Week Price Position
Position in Range: 3.0%
MTVA is currently trading at $1.39, placing it 3.0% of the way from its 52-week low of $0.97 to its 52-week high of $14.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is MetaVia Inc. (MTVA)?
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
MetaVia Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
How to Buy MetaVia Inc. (MTVA) Stock on MEXC
Eligible investors can buy real shares of MetaVia Inc. (MTVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is MetaVia Inc. (MTVA) stock price today?
2.Is MTVA stock going up or down today?
3.What is MTVA pre-market price?
4.What is MTVA after-hours price?
5.Is MTVA stock trading now?
6.Where does MTVA sit relative to its 52-week high and low?
7.What sector is MetaVia Inc. in?
8.What is MetaVia Inc.'s market capitalization and where is it listed?
9.How is MTVA valued in terms of P/E ratio and EPS?
10.Does MetaVia Inc. pay a dividend?
Explore More US Stocks
Search Stocks
MTVA Stock Calculator
Estimate the value between MTVA shares and USD.
MTVA Shares to USD
1.00 MTVA shares = 1.388 USD
Calculations are estimates based on the latest available price and are for reference only.


